Status:
UNKNOWN
Neurobiological and Immunological Mechanisms of Dyspnea in ALS (BIOPNEA)
Lead Sponsor:
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
Conditions:
Shortness of Breath
Dyspnea
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Dyspnea; subjective experience of respiratory discomfort; which produces negative emotional experience, is the most common symptom of patients afflicted with chronic respiratory failure and its treatm...
Eligibility Criteria
Inclusion
- \- Patients with chronic respiratory failure with diaphragmatic dysfunction linked to amyotrophic lateral sclerosis and requiring long-term NIV
Exclusion
- Other respiratory disease (COPD, asthma, obstructive sleep apnea)
- Alcohol or psychotropic drug the lasts 24 hours
- Cognitive impairment
- Smoking \> 10 PA
- Exacerbation or infection 6 weeks earlier
- Endstage of illness
- Chronic or acute pain (VAS \> 3)
Key Trial Info
Start Date :
July 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04332198
Start Date
July 1 2023
End Date
October 1 2024
Last Update
March 4 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.